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Purpose of the study
Truvada (emtricitabine + tenofovir) and Kivexa (abacavir
+ lamivudine) are combination therapies used as the
nucleos(t)ide backbone in combination antiretroviral
therapy. Recent reports have suggested Kivexa may be
inferior to Truvada at high viral load (>100,000 copies/
ml).
Methods
Retrospective case note review. All patients underwent
HLA B5701 testing.
Summary of results
Between April 2006 and April 2008, 87 HAART-naive
patients were commenced on either Truvada or Kivexa in
combination with; efavirenz (53), nevirapine (3), Kaletra
(6), atazanavir/ritonavir (9), other protease inhibitors
(13). In the Truvada group (53), overall mean baseline
viral load (VL) was 122,106 copies/ml. In the Kivexa
group (33), overall mean baseline VL was 99,883 copies/
ml. In order to assess the effect of different initial viral
loads on the response to combination therapy, the
patients were divided into three groups: those with High
(>100,000 copies/ml), Intermediate (10,000 – 100,000
copies/ml) and Low (<10,000 copies/ml) viral loads prior
to commencing HAART. (Table 1.)
Failure to achieve a viral load of less than 1,000 copies/ml
by 4 weeks of therapy is strongly associated with failure to
achieve long-term viral suppression. In the Truvada
group, 67% of all patients achieved this level by 4 weeks
of therapy. In the Kivexa group, 70% of all patients
achieved a viral load of <1,000 copies/ml after 4 weeks of
therapy.
Conclusion
There is no significant difference in clinical practice when
comparing the use of Truvada and Kivexa in patients with
different viral loads at commencement.
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53 20 23 10 33 9 20 4
VL <50 at 3 
months (%)
60 35 74 80 73 60 80 75
Vl < 50 at 4 
months (%)
75 60 87 90 79 78 85 75
VL < 50 at 6 
months (%)
83 80 91 90 91 89 90 100
VL < 1000 at 
4 weeks (%)
67 45 83 70 70 22 85 100Page 2 of 2
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